HALO vs. BIIB, UTHR, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, MDGL, and ALKS
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry.
Halozyme Therapeutics vs.
Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Biogen received 1289 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.47% of users gave Biogen an outperform vote while only 69.53% of users gave Halozyme Therapeutics an outperform vote.
87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.
Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biogen currently has a consensus price target of $213.33, suggesting a potential upside of 50.54%. Halozyme Therapeutics has a consensus price target of $62.78, suggesting a potential upside of 8.31%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.
Biogen has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
In the previous week, Biogen had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 21 mentions for Biogen and 17 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.14 beat Halozyme Therapeutics' score of 0.93 indicating that Biogen is being referred to more favorably in the media.
Summary
Biogen and Halozyme Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HALO) was last updated on 3/4/2025 by MarketBeat.com Staff
